Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 3/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.45 |
| ▸ | HMGCR | P04035 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424259 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL3119123 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL5180314 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL3122448 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL7610120 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL3122405 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL5181358 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL4425881 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL7608679 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS | |
| SCHEMBL7607841 | 1.00 | GPR84 (0.50) | GPR84FFAR1MAPTFFAR4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511500-A4 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | EPIGENESIS PHARMACEUTICALS LLC (US) | 2009-04-29 | — | — | EP | claimed |
| JP-2006504666-A | — | — | 2006-02-09 | — | — | JP | claimed |
| EP-1511500-A2 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | Epigenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| WO-2004014293-A2 | COMBINATION OF ANTI-MUSCARINIC AGENTS AND NON-GLUCOCORTICOID STEROIDS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030216329-A1 | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) | EPEGENESIS PHARMACEUTICALS, INC. | 2003-11-20 | — | — | US | claimed |
| US-6284750-B1 | DRUG, COSMETICS STEROID | ESTEE LAUDER INC. | 2001-09-04 | — | — | US | claimed |
| EP-0876391-B1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC (US) | 2000-08-16 | — | — | EP | claimed |
| US-6025347-A | Steroid esters useful against skin disorders | ESTEE LAUDER INC. (US) | 2000-02-15 | — | — | US | claimed |
| EP-0706509-B1 | SHORT CHAIN 2-HYDROXYCARBOXYLIC ACID-BASED DERIVATIVES OF CERAMIDES | DSM NV (NL) | 2000-01-05 | — | — | EP | claimed |
| US-5948418-A | MERCAPTANS | ESTEE LAUDER, INC. (US) | 1999-09-07 | — | — | US | claimed |
| EP-0876391-A4 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0876391-A1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER INC. (US) | 1998-11-11 | — | — | EP | claimed |
| US-5683705-A | Sulfur-based amides and bis-amides useful against skin disorders | ESTEE LAUDER, INC. (US) | 1997-11-04 | — | — | US | claimed |
| WO-1997010255-A1 | NOVEL STEROID ESTERS USEFUL AGAINST SKIN DISORDERS | ESTEE LAUDER, INC. (US) | 1997-03-20 | — | — | WO | claimed |
| US-20240229188-A9 | SYSTEMS AND METHODS FOR EXTRACTING RARE EARTH ELEMENTS WITH ENGINEERED MICROORGANISMS | CORNELL UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-20240132993-A1 | SYSTEMS AND METHODS FOR EXTRACTING RARE EARTH ELEMENTS WITH ENGINEERED MICROORGANISMS | UNIV CORNELL (US) | 2024-04-25 | — | — | US | disclosed |
| US-20220411846-A1 | METHOD FOR PREDICTING THE VIRULENCE AND PATHOGENICITY OF GRAM-NEGATIVE BACTERIAL STRAINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-12-29 | — | — | US | disclosed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0143840-A1 | MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY. | WISCONSIN ALUMNI RES FOUND (US) | 1985-06-12 | — | — | EP | disclosed |
| WO-1984004526-A1 | MONOSACCHARIDE COMPOUNDS HAVING IMMUNOSTIMULATING ACTIVITY | WISCONSIN ALUMNI RES FOUND (US) | 1984-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216329-A1 | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) | KIT, NR5A1, CHRM5 | GPR84 265/4885FFAR1 1697/4885MAPT 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.